The pharmacology of cyclopropyl-methoxycarbonyl metomidate: a comparison with propofol.
Rile Ge, Ervin Pejo, Hilary Gallin, Spencer Jeffrey, Joseph F Cotten, Douglas E Raines
Index: Anesth. Analg. 118(3) , 563-7, (2014)
Full Text: HTML
Abstract
Cyclopropyl-methoxycarbonyl metomidate (CPMM) is a "soft" etomidate analogue currently being developed as a propofol alternative for anesthetic induction and maintenance.We compared the potencies of CPMM and propofol by assessing their abilities to directly activate α1(L264T)β3γ2 gamma-aminobutyric acid type A (GABAA) receptors and induce loss of righting reflexes in tadpoles. We also measured the rates of encephalographic recovery in rats after CPMM and propofol infusions ranging in duration from 5 to 120 minutes.CPMM and propofol activate GABAA receptors and induce loss of righting reflexes in tadpoles with respective 50% effective concentrations (EC50s) of 3.8 ± 0.4 and 3.9 ± 0.2 μM (GABAA receptor) and 2.6 ± 0.19 and 1.3 ± 0.04 μM (tadpole). Encephalographic recovery after prolonged infusion was faster with CPMM and lacked propofol's context sensitivity.CPMM and propofol have similar potencies in GABAA receptors and tadpoles; however, CPMM provides more rapid and predictable recovery than propofol, particularly after prolonged infusion.
Related Compounds
Related Articles:
2014-12-01
[Anesthesiology 121(6) , 1203-16, (2014)]
2010-09-01
[Fish Physiol. Biochem. 36(3) , 719-30, (2010)]
2006-05-01
[Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 143(1) , 134-9, (2006)]
2003-04-01
[J. Vet. Pharmacol. Ther. 26(2) , 95-103, (2003)]
2012-04-01
[Fish Physiol. Biochem. 38(2) , 401-11, (2012)]